CenterWatch senior edtior to deliver keynote address at KIKA’s U.S. User Group Meeting

KIKA Clinical Solutions announced that Sara Gambrill, Senior Editor of CenterWatch, will be a keynote speaker at KIKA’s U.S. User Group Meeting. KIKA is the leading provider of advanced EDC solutions for clinical trials, and creators of the Veracity™ Web-based platform for Clinical Asset Management. The User Group Meeting will take place October 21 and 22 in Boston.

Sara Gambrill is a highly respected and sought-after speaker in the pharmaceutical arena. She writes insightful feature stories about international and domestic clinical research industry trends regularly for The CenterWatch Monthly and CWWeekly. Ms. Gambrill has also written special reports about various clinical research market regions.

Linda Beneze, CEO of KIKA, said, “We’re thrilled to have a journalist of Sara Gambrill’s caliber and expertise sharing her expertise and insights. It will offer an excellent learning experience for every attendee.”

At KIKA’s meeting Ms. Gambrill will focus on topics including trends and data about technology adoption in the clinical research space. She also will discuss her observations based on her extensive experience in researching and writing about pharmaceutical and biotechnology companies.

http://www.kikaclinicalsolutions.com/

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Research suggests no need for yellow fever vaccine booster after initial dose